On Tuesday, Cathie Wood-led Ark Invest made several significant trades, with the most notable being the purchase of shares in Bullish (NYSE:BLSH).The Bullish TradeArk Invest’s primary trade of the day was in Bullish, a cryptocurrency exchange backed by billionaire investor and entrepreneur Peter Thiel. The firm purchased shares of Bullish through three of its funds – Ark Fintech Innovation ETF (BATS:ARKF), ARK Innovation ETF (BATS:ARKK), and ARK Next Generation Internet ETF (BATS:ARKW). The total number of ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.24%. A quarter ago, it was expected that this company would post a loss of $1.04 per share when it actually produced a loss of $1, delivering a surprise of +3.85%.Over the last four quarters, the company has su ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-5238376 (State or other jurisdiction of incorporation or organization) Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIO ...

Exhibit 99.1 Mr. Evans continued, "In addition, we are thrilled for the Orbital Therapeutics team following its proposed acquisition by Bristol Myers Squibb, indicating the significant potential of Orbital's platform and pipeline. Beam contributed capabilities and technology in mRNA and targeted lipid nanoparticles to Orbital, and this outcome further validates our innovative platform strategy to unlock additional shareholder value in non-core areas and accelerate the creation of new medicines for patients. ...

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026 Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting First Subject Dosed with BEAM-103, ESCAPE Anti-CD117 Monoclonal Antibody, in Healthy Volunteer Trial Ended Third Quarter 2025 with $1.1 Billion in Cas ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando. BEAM-101 is an investigational genetically modifie ...

A downtrend has been apparent in Beam Therapeutics Inc. (BEAM) lately. While the stock has lost 11.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the fut ...

公司业绩预期 - 市场预计公司在截至2025年9月的季度将出现每股0.98美元的亏损，但同比改善16.2% [3] - 预计季度营收为1299万美元，较去年同期下降9% [3] - 过去30天内，市场对公司的季度共识每股收益预期上调了5.19% [4] 盈利预测模型分析 - 公司的“最准确预期”低于“Zacks共识预期”，导致其盈利ESP为-9.41%，表明分析师近期对其盈利前景转趋悲观 [12] - 公司目前的Zacks评级为第2级（买入） [12] - 盈利ESP为负值且Zacks评级为第2级的组合，使得难以确定性地预测公司业绩将超出预期 [12] 历史业绩表现 - 在上一个报告季度，公司实际每股亏损1.00美元，优于预期的每股亏损1.04美元，实现了3.85%的正向意外 [13] - 在过去四个季度中，公司有两次业绩超出市场共识预期 [14] 行业对比 - 同属医疗-生物医学和遗传学行业的Sarepta Therapeutics预计季度每股亏损0.03美元，同比变化-104.8% [18] - Sarepta Therapeutics预计季度营收为3.4623亿美元，同比下降25.9% [19] - Sarepta Therapeutics的共识每股收益预期在过去30天内上调13.1%，且其极高的正盈利ESP（+1,733.32%）结合第3级（持有）评级，表明其很可能超出盈利预期 [19][20]

盘前交易概况 - 美国东部时间周一上午8点45分，多只股票在盘前交易中出现显著波动，早期价格变动预示着开盘前的潜在机会 [1] - 盘前交易为活跃交易者提供了识别潜在突破、反转或剧烈价格波动的先机，这些早期动向通常预示着动能可能延续至常规交易时段 [1] 盘前涨幅居前股票 - Click Holdings Limited (CLIK) 涨幅最大，达81%，股价为11.17美元 [3] - Avidity Biosciences, Inc. (RNA) 上涨43%，股价为70.72美元 [3] - Dyne Therapeutics, Inc. (DYN) 上涨37%，股价为23.58美元 [3] - Zenas BioPharma, Inc. (ZBIO) 上涨21%，股价为29.00美元 [3] - ProPetro Holding Corp. (PUMP) 上涨18%，股价为7.47美元 [3] - 生物科技与医药行业公司表现突出，在涨幅前十的股票中占据多数席位 [3] 盘前跌幅居前股票 - Smart Logistics Global Limited (SLGB) 跌幅最大，达37%，股价为3.21美元 [4] - MaxsMaking Inc. (MAMK) 下跌22%，股价为4.08美元 [4] - Prenetics Global Limited (PRE) 下跌14%，股价为14.40美元 [4] - United States Antimony Corporation (UAMY) 下跌14%，股价为10.22美元 [4] - NeurAxis, Inc. (NRXS) 下跌12%，股价为3.01美元 [4] - 物流、金属及 therapeutics 行业部分公司出现显著下跌 [4]

公司业务与定位 - 公司是精密基因公司 专注于碱基编辑技术领域 [1] - 致力于开发针对血液和肝脏遗传疾病的一次性离体和体内疗法 目标是实现持久的、可能具有功能性的治愈效果 [1]